198 related articles for article (PubMed ID: 24297954)
21. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
[TBL] [Abstract][Full Text] [Related]
22. Malignant melanoma in Turkey: a single institution's experience on 475 cases.
Tas F; Kurul S; Camlica H; Topuz E
Jpn J Clin Oncol; 2006 Dec; 36(12):794-9. PubMed ID: 17060409
[TBL] [Abstract][Full Text] [Related]
23. Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas.
Chen T; Fallah M; Försti A; Kharazmi E; Sundquist K; Hemminki K
JAMA Dermatol; 2015 Jun; 151(6):607-15. PubMed ID: 25671687
[TBL] [Abstract][Full Text] [Related]
24. The importance of self-examination in the earliest diagnosis of multiple primary cutaneous melanomas: a report of 47 cases.
Manganoni AM; Farisoglio C; Tucci G; Facchetti F; Calzavara Pinton PG
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1333-6. PubMed ID: 17958838
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
26. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.
Tas F; Keskin S; Karadeniz A; Dağoğlu N; Sen F; Kilic L; Yildiz I
Oncology; 2011; 81(5-6):353-8. PubMed ID: 22248874
[TBL] [Abstract][Full Text] [Related]
27. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
28. Primary malignant melanoma of skin in four regions of New Zealand.
Cooke K; McNoe B; Hursthouse M; Taylor R
N Z Med J; 1992 Aug; 105(939):303-6. PubMed ID: 1501812
[TBL] [Abstract][Full Text] [Related]
29. Merkel cell carcinoma: incidence, mortality, and risk of other cancers.
Kaae J; Hansen AV; Biggar RJ; Boyd HA; Moore PS; Wohlfahrt J; Melbye M
J Natl Cancer Inst; 2010 Jun; 102(11):793-801. PubMed ID: 20424236
[TBL] [Abstract][Full Text] [Related]
30. [Increased risk of developing a second primary cutaneous nevus-associated melanoma in patients previously diagnosed with the disease].
Echeverría B; Botella-Estrada R; Serra-Guillén C; Martorell A; Traves V; Requena C; Sanmartín O; Llombart B; Guillén C; Nagore E
Actas Dermosifiliogr; 2010 Oct; 101(8):710-6. PubMed ID: 20965014
[TBL] [Abstract][Full Text] [Related]
31. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma.
Turner RM; Bell KJ; Morton RL; Hayen A; Francken AB; Howard K; Armstrong B; Thompson JF; Irwig L
J Clin Oncol; 2011 Dec; 29(35):4641-6. PubMed ID: 22067399
[TBL] [Abstract][Full Text] [Related]
32. Clinical stages of cutaneous malignant melanoma in Bulgaria.
Troyanova P; Valerianova Z; Danon S
Neoplasma; 2000; 47(4):257-60. PubMed ID: 11043833
[TBL] [Abstract][Full Text] [Related]
33. Trends in the risks of melanoma as a second primary cancer among cancer patients in the Netherlands, 1989-2008.
Liu L; Soerjomataram I; Nijsten T; van der Aa M; van der Leest R; Coebergh JW; de Vries E
Melanoma Res; 2013 Jun; 23(3):206-12. PubMed ID: 23458761
[TBL] [Abstract][Full Text] [Related]
34. [Stage distribution of malignant melanomas in a Hungarian centre].
Tóth V; Somlai B; Hársing J; Hatvani Z; Kárpáti S
Orv Hetil; 2013 Jun; 154(25):969-76. PubMed ID: 23774804
[TBL] [Abstract][Full Text] [Related]
35. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma.
DiFronzo LA; Wanek LA; Elashoff R; Morton DL
Ann Surg Oncol; 1999; 6(7):705-11. PubMed ID: 10560858
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
37. Multiple primary melanoma: incidence and risk factors in 283 patients.
Slingluff CL; Vollmer RT; Seigler HF
Surgery; 1993 Mar; 113(3):330-9. PubMed ID: 8441968
[TBL] [Abstract][Full Text] [Related]
38. Risk of second primary in situ and invasive melanoma in a Dutch population-based cohort: 1989-2008.
van der Leest RJ; Liu L; Coebergh JW; Neumann HA; Mooi WJ; Nijsten T; de Vries E
Br J Dermatol; 2012 Dec; 167(6):1321-30. PubMed ID: 22759226
[TBL] [Abstract][Full Text] [Related]
39. Elevated risk of second primary cancer in patients with cutaneous malignant melanoma: a nationwide cohort study in Taiwan.
Hwang CY; Chen YJ; Lin MW; Chen TJ; Chu SY; Chen CC; Lee DD; Chang YT; Wan WJ; Liu HN
J Dermatol Sci; 2010 Dec; 60(3):167-72. PubMed ID: 21036546
[TBL] [Abstract][Full Text] [Related]
40. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002.
Coory M; Baade P; Aitken J; Smithers M; McLeod GR; Ring I
Cancer Causes Control; 2006 Feb; 17(1):21-7. PubMed ID: 16411049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
